Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24594126 | 0.83 | FGFR1 (0.41) | FGFR1FGFR4EGFRUCHL3FGFR2 | |
| SCHEMBL29214294 | 0.82 | FGFR4 (0.39) | FGFR1FGFR4EGFRUCHL3TSHR | |
| SCHEMBL23044892 | 0.81 | HTR4 (0.39) | TSHRMAPTPOLBLMNAMAPK10 | |
| SCHEMBL23044916 | 0.78 | FGFR1 (0.39) | FGFR1FGFR4EGFRTSHRMAPT | |
| SCHEMBL23044886 | 0.78 | FGFR4 (0.44) | FGFR1FGFR4LMNAFGFR2KDR | |
| SCHEMBL24594012 | 0.77 | FGFR1 (0.39) | FGFR1FGFR4EGFRTSHRMAPT | |
| SCHEMBL23044921 | 0.77 | HTT (0.44) | EGFRUCHL3TSHRMAPTLMNA | |
| SCHEMBL23060175 | 0.77 | BID (0.40) | FGFR1FGFR4EGFRTSHRMAPT | |
| SCHEMBL23060182 | 0.77 | FGFR1 (0.39) | FGFR1FGFR4EGFRTSHRMAPT | |
| SCHEMBL23060232 | 0.73 | FGFR1 (0.34) | FGFR1FGFR4EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114728910-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021037219-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 上海奕拓医药科技有限责任公司 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR4 4/4885EGFR 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.